ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Athira Pharma Inc

Athira Pharma Inc (ATHA)

0.5281
0.0183
(3.59%)
마감 16 9월 5:00AM
0.535
0.0069
(1.31%)
시간외 거래: 8:55AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.535
매수가
0.5052
매도가
0.53
거래량
786,870
0.51 일간 변동폭 0.54385
0.4649 52주 범위 16.65
market_cap
전일 종가
0.5098
개장가
0.5237
최근 거래 시간
1
@
0.535
마지막 거래 시간
재정 규모
US$ 413,874
VWAP
0.525976
평균 볼륨(3m)
428,607
발행 주식
38,439,375
배당수익률
-
주가수익률
-0.17
주당순이익(EPS)
-3.06
매출
1.63M
순이익
-117.67M

Athira Pharma Inc 정보

Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease. Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

섹터
Biological Pds,ex Diagnstics
산업
Biological Pds,ex Diagnstics
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
Athira Pharma Inc is listed in the Biological Pds,ex Diagnstics sector of the 나스닥 with ticker ATHA. The last closing price for Athira Pharma was US$0.51. Over the last year, Athira Pharma shares have traded in a share price range of US$ 0.4649 to US$ 16.65.

Athira Pharma currently has 38,439,375 shares in issue. The market capitalisation of Athira Pharma is US$19.60 million. Athira Pharma has a price to earnings ratio (PE ratio) of -0.17.

ATHA 최신 뉴스

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23)  In pre-specified subgroups of patients with moderate Alzheimer’s...

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Topline data from completed Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease targeted for September 2024 Phase 2/3 LIFT-AD data to...

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment, alone...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-2.465-82.166666666733.670.464918047510.92091976CS
4-1.735-76.43171806172.273.670.46496764671.16212776CS
12-1.985-78.76984126982.523.670.46494286071.51953982CS
26-1.525-74.02912621362.064.29840.46493626651.98812051CS
52-10.495-95.149592021811.0316.650.46493752214.67288687CS
156-19.415-97.318295739319.9534.790.46494234178.35039753CS
2600000.5796000CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
NOVVUNova Vision Acquisition Corporation
US$ 41.00
(207.35%)
17.4k
NOVVNova Vision Acquisition Corporation
US$ 37.0001
(200.08%)
202.75k
SMXSMX Security Matters Public Company
US$ 5.85
(138.78%)
49.72M
OMICSingular Genomics Systems Inc
US$ 12.38
(119.12%)
2.72M
TILInstill Bio Inc
US$ 84.75
(82.41%)
3.76M
GSIWGarden Stage Ltd
US$ 2.9693
(-75.66%)
4.24M
UPCUniverse Pharmaceuticals Inc
US$ 0.55
(-67.07%)
30.45M
VMARVision Marine Technologies Inc
US$ 0.77
(-48.67%)
34.54M
PRLDPrelude Therapeutics Inc
US$ 2.775
(-42.55%)
2.49M
CNEYCN Energy Group Inc
US$ 0.4335
(-37.17%)
5.06M
NVDANVIDIA Corporation
US$ 119.10
(-0.03%)
238.43M
XXII22nd Century Group Inc
US$ 0.3447
(28.00%)
183.73M
IMRXImmuneering Corporation
US$ 2.02
(41.26%)
136.36M
SQQQProShares UltraPro Short QQQ
US$ 8.17
(-1.33%)
127.78M
MULNMullen Automotive Inc
US$ 0.1328
(-20.48%)
120.81M

ATHA Discussion

게시물 보기
stockyupydowny stockyupydowny 6 일 전
Some life coming back into play with this one, the 400 million cash injection deal that takes the to the $1 billion dollar deal they made will be reflected with patience
👍️0
Saving Grace Saving Grace 2 주 전
ATHA under .65 cents and plunging.
👍️0
Monksdream Monksdream 2 주 전
ATHA under $4
👍️0
Monksdream Monksdream 2 월 전
ATHA under $3
👍️0
Monksdream Monksdream 4 월 전
ATHA under $3
👍️0
glenn1919 glenn1919 6 월 전
ATHA..............................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 6 월 전
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
👍️0
Whalatane Whalatane 7 월 전
4:22 PM ET 02/14/2024
http://archive.fast-edgar.com/20240214/A3BEF62C8M22CZZ2222M2ZZZ5PKQZ2U2X262
Filed on: February 14, 2024

Baker Bros position
-------
Kiwi
👍️0
Whalatane Whalatane 8 월 전
“The new year is off to a strong start with the completion of enrollment in our Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease (AD), which we expect will enable topline data readout from the study in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
“The potential of fosgonimeton as a treatment for AD is supported by the independent, unblinded interim efficacy and futility analysis of the first 100 subjects in the Phase 2/3 LIFT-AD study and the results from the exploratory Phase 2 ACT-AD clinical trial, which showed potential congruent improvements in biomarkers of neurodegeneration, inflammation and Alzheimer’s disease protein pathologies as well as measures of cognition and function.”

“The totality of data shared to date strengthens our confidence in and supports the potential of our small molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The consistency of data from preclinical models across various neurodegenerative diseases and in Alzheimer’s patients suggests that our small molecule drug candidates may be neuroprotective, neurotrophic, procognitive and potentially disease-modifying. This includes our recently reported findings from the exploratory SHAPE Phase 2 clinical trial, the results of which showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.”


Kiwi
👍️0
Whalatane Whalatane 8 월 전
ATHA their P2/3 Alzheimer trial now fully enrolled.
Data in about 9 mths
They had an interim analysis run by an independent DMC ....Did not stop for futility . DMC said increase size of trial to power for statistically significant results ....so trial likely to show benefit .
Question is ....will the degree of benefit be clinically relevant .
-------------
Kiwi
👍️0
Whalatane Whalatane 8 월 전
The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA... what a bio beast running through the streets...watch the explosion on the horizon...
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
What a day…what a stock!!!
👍️0
great_tree great_tree 3 년 전
Any serious comments on their product vs. SAVA, CRTX, AVXL etc.?
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA pushing hard into close
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA bio beast is very mad. She wants to fill that gap
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA is ready to move big next week, the best bio taking on Alzheimers
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA starting to heat up..love this bio beast!!!
👍️0
TrendTrade2016 TrendTrade2016 3 년 전
ATHA another bio beast ready to beast
👍️0
maximumgriff maximumgriff 3 년 전
Girt prices
👍️0
crudeoil24 crudeoil24 4 년 전
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
👍️0
crudeoil24 crudeoil24 4 년 전
Athira Pharma started at buy with $36 stock price target at Stifel Nicolaus.
👍️0

최근 히스토리

Delayed Upgrade Clock